Editas Medicine is on track to “make history” with the enrollment of its in vivo CRISPR genome-editing technology clinical trial, CEO Cynthia Collins said at the J.P. Morgan Healthcare Conference.
“We are entering 2020 with strong momentum and a strategic focus on driving our pipeline of in vivo CRISPR and engineered cell medicines forward with the ultimate vision of developing differentiated, transformational medicines for people living with serious diseases,” Collins said.
EDIT-101, which is targeting genetic blindness, removes the genetic mutation that causes
Uncategorized